March 22, 2019Expert Review of Cardiovascular Therapy
Edoxaban for the prevention of stroke in patients with atrial fibrillation
Key result
Edoxaban 60 mg was noninferior to warfarin for the prevention of stroke or systemic embolism, and significantly reduced the risk of bleeding, major adverse cardiac events and cardiovascular death.
Why the study?
A large number of substudies, post hoc analyses, and observational studies have been published following the pivotal ENGAGE AF-TIMI 48 trial, prompting an updated review of evidence on edoxaban in AF patients.
Does edoxaban 60 mg once daily prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Population
Patients with AF
Comparison
Edoxaban vs warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports edoxaban as cost-effective AF option; leaves open real-world economic validation in broader populations.
Structured PICO
Does edoxaban 60 mg once daily prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
P
Population
Patients with nonvalvular atrial fibrillation
I
Intervention
Edoxaban 60 mg once daily
C
Comparator
Warfarin
O
Outcome
Prevention of stroke or systemic embolismcomposite
Edoxaban 60 mg is an effective and safe alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation across various clinical conditions.
Limitations
- Data about the effectiveness and safety of edoxaban in real-life patients are scarce.
- Data about the effectiveness and safety of edoxaban in real-life patients are scarce
Cite This Study
Escobar et al. (2019) conducted a review in nonvalvular atrial fibrillation. Edoxaban vs. warfarin was evaluated on stroke or systemic embolism. Edoxaban 60 mg was noninferior to warfarin for the prevention of stroke or systemic embolism, and significantly reduced the risk of bleeding, major adverse cardiac events and cardiovascular death.